EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of patiromer for non-dialysis and dialysis patients with hyperkalemia: the randomized, placebo-controlled and long-term study

Naoki Kashihara, Yasuro Kumeda, Yorihiko Higashino, Yoshitaka Maeda, Yoko Kaneko, Hidetoshi Kanai, Yuko Taniguchi, Takayuki Ishii, Yusuke Tomioka

Clinical and Experimental Nephrology · 2025

DOI: 10.1007/s10157-024-02585-5 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Experimental Nephrology, 2025. Verfasst von Naoki Kashihara und 8 weiteren Autor:innen. Beteiligte Einrichtung: Kawasaki Medical School, Okayama, Japan. Hauptthemen laut MEDLINE: Hyperkalemia, Polymers, Potassium. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca, Gilead Sciences, Kyowa Kirin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The objectives of this phase two study are to investigate the efficacy of two starting doses of 8.4 g and 16.8 g and evaluate the long-term safety of patiromer in Japanese patients with hyperkalemia.

Methods

This study comprised three cohorts; non-dialysis patients with baseline serum potassium (sK) level of 5.1 to < 6.0 mmol/L (NDC1); 6.0 to < 6.5 mmol/L (NDC2); dialysis patients with baseline sK level of 5.5 to < 6.5 mmol/L (DC). The study design was one-week, randomized, double-blind, placebo-controlled, and open label extension for one year in NDC1, open label during the study in NDC2 and DC. Patients were randomly assigned to patiromer 8.4 g, 16.8 g or placebo in NDC1, 8.4 g or 16.8 g in NDC2 and DC. Dose was adjusted up to 25.2 g according to the titration algorism in open label period.

Results

A total of 185 patients were randomized (NDC1:153, NDC2:10, and DC:22). The primary endpoint of the change in least squares mean sK levels at Week 1 in NDC1 was – 0.55, – 0.77 and – 0.10 mmol/L for the 8.4 g, 16.8 g and placebo group ( P < 0.001 for the patiromer group vs the placebo group). In all cohorts for each patiromer group, more than 80% of patients achieved normal sK at Week 5. There was no severe treatment-related adverse event.

Conclusion

Treatment with patiromer was effective in lowering and maintaining target sK levels, also well tolerated for one year in Japanese patients with hyperkalemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperkalemiaPolymersPotassiumHumansMaleFemaleMiddle AgedAgedDouble-Blind MethodRenal DialysisTreatment OutcomeTime FactorsJapanAdultBiomarkersAged, 80 and over

Stichwörter der Autor:innen

HyperkalemiaLong-term safetyPatiromerPhase IIPlacebo-controlled

Substanzen

PolymersPotassiumpatiromerBiomarkers

Autor:innen und Institutionen

  • Kawasaki Medical School, Okayama, Japan.
  • Minamiosaka Hospital, Osaka, Japan.
  • Higashi Takarazuka, Satoh Hospital, Hyogo, Japan.
  • JA Toride Medical Center, Ibaraki, Japan.
  • Tsukuba Central Hospital, Ibaraki, Japan.
  • Kokura Memorial Hospital, Fukuoka, Japan.

Förderung

  • AstraZeneca
  • Gilead Sciences
  • Kyowa Kirin
  • GlaxoSmithKline Japan
  • Daiichi-Sankyo
  • Takeda Pharmaceutical Company
  • Astellas Pharma
  • Otsuka Pharmaceutical

Zitieren

APA

Kashihara, N., Kumeda, Y., Higashino, Y., Maeda, Y., Kaneko, Y., Kanai, H., Taniguchi, Y., Ishii, T., & Tomioka, Y. (2025). Efficacy and safety of patiromer for non-dialysis and dialysis patients with hyperkalemia: the randomized, placebo-controlled and long-term study. Clinical and Experimental Nephrology. https://doi.org/10.1007/s10157-024-02585-5

Vancouver

Kashihara N, Kumeda Y, Higashino Y, Maeda Y, Kaneko Y, Kanai H, et al. Efficacy and safety of patiromer for non-dialysis and dialysis patients with hyperkalemia: the randomized, placebo-controlled and long-term study. Clinical and Experimental Nephrology. 2025. doi:10.1007/s10157-024-02585-5

BibTeX
@article{Kashihara2025,
  author = {Kashihara, Naoki and Kumeda, Yasuro and Higashino, Yorihiko and Maeda, Yoshitaka and Kaneko, Yoko and Kanai, Hidetoshi and Taniguchi, Yuko and Ishii, Takayuki and Tomioka, Yusuke},
  title = {Efficacy and safety of patiromer for non-dialysis and dialysis patients with hyperkalemia: the randomized, placebo-controlled and long-term study},
  journal = {Clinical and Experimental Nephrology},
  year = {2025},
  doi = {10.1007/s10157-024-02585-5}
}
Kostenlos starten →